WELL Health Technologies Corp (WELL) AI Stock Analysis

• Market Cap: C$1.26B
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 26.20%
• EPS Growth: -156.86%
• Country: CA
• Employees: 1,507
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.16
• Shares Outstanding: 253,894,040
• 10 Day Avg. Volume: 1,712,971
• 30 Day Avg. Volume: 1,366,290
• PEG Ratio: <0.01
• Price to Book (P/B): 1.95
• Price to Sales (P/S): 1.84
• P/FCF Ratio: -252.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$7.60
• Price Target Upside: 99.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$3.50 ▼(-8.14% Downside)

WELL Health Technologies Corp's overall score is driven by strong revenue growth and positive earnings call sentiment. However, significant challenges in profitability, cash flow management, and bearish technical indicators weigh heavily on the score.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth indicates strong market demand and effective business strategies, enhancing long-term market position.

EBITDA Improvement

The substantial increase in EBITDA reflects improved operational efficiency and cost management, supporting sustainable profitability.

Canadian Clinics Performance

The robust growth in Canadian clinics underscores the company's strong market presence and potential for continued expansion in healthcare services.

Negative Factors

Profitability Challenges

Ongoing profitability issues could hinder reinvestment and growth opportunities, affecting long-term financial health and shareholder returns.

Cash Flow Management

Negative free cash flow indicates potential liquidity issues, limiting the company's ability to fund operations and strategic initiatives.

Circle Medical Performance

Declining revenues in Circle Medical highlight operational challenges that could impact overall growth and require strategic adjustments.

WELL Health Technologies Corp Business Overview & Revenue Model

Company Description

WELL Health Technologies Corp (WELL) is a Vancouver-based digital health company focused on empowering healthcare providers and patients through innovative technology solutions. The company operates primarily in the healthcare sector, offering a range of services that include telehealth, electronic medical records (EMR) solutions, and patient engagement platforms. WELL's core products aim to enhance access to healthcare, streamline clinical workflows, and improve patient outcomes, making it a key player in the digital transformation of healthcare services.

How the Company Makes Money

WELL Health generates revenue through multiple streams, primarily by providing software and technology solutions to healthcare providers. Key revenue sources include subscription fees for its EMR systems, transaction fees from telehealth consultations, and sales of patient engagement tools. Additionally, WELL benefits from partnerships with various healthcare organizations and institutions, which enable it to expand its service offerings and reach a broader customer base. The company also explores opportunities in acquisitions to enhance its technology portfolio and increase market share, contributing to its overall earnings.

WELL Health Technologies Corp Financial Statement Overview

Summary

WELL Health Technologies Corp is experiencing strong revenue growth, but profitability and cash flow management remain areas of concern. The balance sheet is relatively stable, but the company needs to address its negative profitability and improve cash flow conversion to enhance financial health.

Income Statement

WELL Health Technologies Corp has shown a positive revenue growth rate of 11.56% in the TTM, indicating a strong upward trajectory in sales. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased over time, reflecting potential cost management issues.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.57, suggesting a balanced approach to leveraging. However, the negative return on equity in the TTM indicates challenges in generating returns for shareholders. The equity ratio is stable, showing a solid capital structure.

Cash Flow

The cash flow statement reveals a significant improvement in free cash flow growth rate, but the free cash flow remains negative. The operating cash flow to net income ratio is low, indicating potential issues in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.10B	919.69M	776.05M	569.14M	302.32M	50.24M
Gross Profit	429.62M	363.01M	372.27M	303.29M	153.69M	21.22M
EBITDA	-19.20M	122.52M	101.88M	95.07M	21.27M	-495.00K
Net Income	-128.62M	32.61M	82.00K	19.07M	-30.69M	-2.62M
Balance Sheet
Total Assets	2.02B	1.81B	1.41B	1.32B	1.26B	262.73M
Cash, Cash Equivalents and Short-Term Investments	98.89M	131.67M	43.42M	48.91M	61.92M	86.89M
Total Debt	569.76M	425.09M	426.28M	358.42M	401.94M	23.57M
Total Liabilities	1.03B	877.55M	563.16M	503.78M	554.37M	43.75M
Stockholders Equity	826.20M	867.61M	767.67M	732.34M	618.24M	217.37M
Cash Flow
Free Cash Flow	-17.33M	-6.70M	37.20M	70.14M	19.59M	-6.52M
Operating Cash Flow	3.93M	9.52M	66.44M	76.55M	22.27M	-5.38M
Investing Cash Flow	-86.18M	-60.23M	-106.42M	-37.93M	-499.78M	-44.21M
Financing Cash Flow	133.09M	133.50M	10.63M	-52.85M	452.53M	120.84M

WELL Health Technologies Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WELL, the sentiment is Negative. The current price of 3.81 is below the 20-day moving average (MA) of 4.31, below the 50-day MA of 4.83, and below the 200-day MA of 4.66, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 27.00 is Positive, neither overbought nor oversold. The STOCH value of 37.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:WELL.

WELL Health Technologies Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DNTL	64 Neutral	C$2.17B	-46.32	-1.56%	0.69%	10.09%	67.54%
DR	63 Neutral	$269.83M	2.05	39.85%	2.35%	-40.05%	558.77%
NLH	60 Neutral	C$26.19M	157.89	4.10%	―	19.61%	―
CRRX	52 Neutral	C$229.69M	3,650.00	0.11%	0.56%	0.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WELL	46 Neutral	C$1.26B	-9.60	-5.11%	―	26.20%	-156.86%

WELL Health Technologies Corp Corporate Events

WELL Health Technologies Achieves Record Q3-2025 Financial Results

WELL Health Technologies Corp reported record financial results for Q3-2025, with revenues reaching $364.6 million, a 56% increase from the previous year, driven by organic growth and acquisitions. The company achieved a record Adjusted EBITDA of $59.9 million, marking a 296% increase, and highlighted improvements in operational efficiency and patient visits in its Canadian clinics. WELLSTAR, a majority-owned subsidiary, secured $62 million in financing, reflecting strong market confidence and positioning it for future growth and an IPO.

The most recent analyst rating on (TSE:WELL) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELLSTAR Technologies Secures C$62 Million for Growth Ahead of Spinout

WELL Health Technologies Corp’s subsidiary, WELLSTAR Technologies, has announced a C$62 million equity placement to support its growth strategy ahead of a planned spinout. The financing, backed by prominent Canadian investors, is expected to close in December 2025 and will be used for AI innovation, acquisitions, and organic growth. This move highlights investor confidence in WELLSTAR’s performance and positions the company for a public listing in 2026, offering direct investment opportunities in a high-growth healthcare technology firm.

The most recent analyst rating on (TSE:WELL) stock is a Hold with a C$5.25 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Technologies to Release Q3 2025 Financial Results

WELL Health Technologies Corp. announced it will release its Fiscal Third Quarter 2025 financial results on November 6, 2025. The company will hold a conference call and webcast on the same day to discuss the results, which could provide insights into its operational performance and market positioning.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Technologies Achieves Record Q2-2025 Results and Milestone Patient Visits

WELL Health Technologies Corp reported record financial results for Q2-2025, achieving a 57% increase in quarterly revenues to $356.7 million, driven by organic growth and acquisitions. The company also marked its first-ever quarter with over 1 million patient visits in Canada, reflecting a 38% year-over-year growth. WELL’s strategic investments in Canadian clinics and technology have led to improved provider productivity and significant milestones in financial metrics, including Adjusted EBITDA and net income. The inclusion of HEALWELL AI contributed $40.5 million to revenue, and the company is considering strategic alternatives for its U.S. assets to focus on core Canadian operations.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.